[Staphylokinase].
Myocardial infarction is due to thrombotic occlusion of a coronary artery. Current thrombolytic agents have demonstrated their major value by inducing a significant reduction of mortality, but they nevertheless present certain limits: 1) excellent arterial patency is obtained in only about 50% of cases; 2) reocclusions persist in 5 to 10% of cases; 3) very severe complications, such as cerebral haemorrhages, have not disappeared (about 0.5% of cases). There is therefore a large field of action for development of the optimal thrombolytic agent. Research concerning staphylokinase, classified among third generation thrombolytic agents, is therefore situated in this context. Staphylokinase is a protein known to possess profibrinolytic properties for more than four decades, but has been the subject of renewed interest over recent years. This article reviews the characteristics, mechanism of action and fibrinolytic properties of staphylokinase. It recalls the main results obtained in animal models and summarizes the main clinical trials in man.
Helft
G
G
Clinique Cardiologique, Hôpital Necker, Paris.
Lebrazi
J
J
Elalamy
I
I
Beygui
F
F
Le Feuvre
C
C
Metzger
J P
JP
Vacheron
A
A
Samama
M M
MM
D000818:Animals; D001426:Bacterial Proteins / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008666:Metalloendopeptidases / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy*
D001426:Bacterial Proteins; D005343:Fibrinolytic Agents; D008666:Metalloendopeptidases; C022653:auR protein, Staphylococcus aureus